Shaanxi Kanghui Pharm vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shaanxi Kanghui Pharm Co Ltd (603139.CG)

Q3 202614 Jul – 16 Sep 2026

▲2▼2

Kanghui pivots to AI computing power with huge contracts, but debt and weak core pharma weigh

New AI computing power contracts worth up to 2.4 billion yuan Kanghui's subsidiary signed two computing power service contracts: one worth 415-679 million yuan in July and another worth 1.72 billion yuan in September. These deals show real demand for its new AI computing business, which could bring in steady revenue over five years and help offset weak traditional medicine sales.
These large contracts are the main new growth driver and explain why the stock has nearly doubled this year.
Debt to fund 1.14 billion yuan server purchase To fulfill the big computing contract, Kanghui must buy 1.14 billion yuan of servers, mostly with borrowed money. This will push its debt ratio from 69% to about 78%, increasing financial risk. The company also said the deal's impact on 2026 profit is uncertain, so the market may worry about the cost of this expansion.
This is the main counterweight: the growth comes with significantly higher debt and uncertain near-term profit.
First-half profit turns positive, but only thanks to asset sales Kanghui reported a net profit of 9.09 million yuan for the first half, reversing a loss. However, the profit came mainly from selling idle assets, while the core business still lost money on an adjusted basis. Revenue also fell 17%. This shows the underlying medicine business remains weak.
The profit turnaround is a headline positive, but the reliance on one-off gains and falling revenue is a real concern for future earnings.
Divesting troubled subsidiary Chunsheng Pharmaceutical Kanghui is selling its 51% stake in Chunsheng Pharmaceutical for 64 million yuan, after the unit repeatedly missed profit targets and the original owners couldn't pay compensation. The sale price is only 12.7% above the original investment, so it's a loss-making exit. This removes a drag but also signals past acquisition troubles.
This divestiture is a negative event that highlights management challenges and past poor performance, affecting investor confidence.

August 202614 Jul – 16 Sep 2026

▲2▼2

Kanghui pivots to AI computing power with huge contracts, but debt and weak core pharma weigh

New AI computing power contracts worth up to 2.4 billion yuan Kanghui's subsidiary signed two computing power service contracts: one worth 415-679 million yuan in July and another worth 1.72 billion yuan in September. These deals show real demand for its new AI computing business, which could bring in steady revenue over five years and help offset weak traditional medicine sales.
These large contracts are the main new growth driver and explain why the stock has nearly doubled this year.
Debt to fund 1.14 billion yuan server purchase To fulfill the big computing contract, Kanghui must buy 1.14 billion yuan of servers, mostly with borrowed money. This will push its debt ratio from 69% to about 78%, increasing financial risk. The company also said the deal's impact on 2026 profit is uncertain, so the market may worry about the cost of this expansion.
This is the main counterweight: the growth comes with significantly higher debt and uncertain near-term profit.
First-half profit turns positive, but only thanks to asset sales Kanghui reported a net profit of 9.09 million yuan for the first half, reversing a loss. However, the profit came mainly from selling idle assets, while the core business still lost money on an adjusted basis. Revenue also fell 17%. This shows the underlying medicine business remains weak.
The profit turnaround is a headline positive, but the reliance on one-off gains and falling revenue is a real concern for future earnings.
Divesting troubled subsidiary Chunsheng Pharmaceutical Kanghui is selling its 51% stake in Chunsheng Pharmaceutical for 64 million yuan, after the unit repeatedly missed profit targets and the original owners couldn't pay compensation. The sale price is only 12.7% above the original investment, so it's a loss-making exit. This removes a drag but also signals past acquisition troubles.
This divestiture is a negative event that highlights management challenges and past poor performance, affecting investor confidence.

Latest14 Jul – 16 Sep 2026

▲2▼2

Kanghui pivots to AI computing power with huge contracts, but debt and weak core pharma weigh

New AI computing power contracts worth up to 2.4 billion yuan Kanghui's subsidiary signed two computing power service contracts: one worth 415-679 million yuan in July and another worth 1.72 billion yuan in September. These deals show real demand for its new AI computing business, which could bring in steady revenue over five years and help offset weak traditional medicine sales.
These large contracts are the main new growth driver and explain why the stock has nearly doubled this year.
Debt to fund 1.14 billion yuan server purchase To fulfill the big computing contract, Kanghui must buy 1.14 billion yuan of servers, mostly with borrowed money. This will push its debt ratio from 69% to about 78%, increasing financial risk. The company also said the deal's impact on 2026 profit is uncertain, so the market may worry about the cost of this expansion.
This is the main counterweight: the growth comes with significantly higher debt and uncertain near-term profit.
First-half profit turns positive, but only thanks to asset sales Kanghui reported a net profit of 9.09 million yuan for the first half, reversing a loss. However, the profit came mainly from selling idle assets, while the core business still lost money on an adjusted basis. Revenue also fell 17%. This shows the underlying medicine business remains weak.
The profit turnaround is a headline positive, but the reliance on one-off gains and falling revenue is a real concern for future earnings.
Divesting troubled subsidiary Chunsheng Pharmaceutical Kanghui is selling its 51% stake in Chunsheng Pharmaceutical for 64 million yuan, after the unit repeatedly missed profit targets and the original owners couldn't pay compensation. The sale price is only 12.7% above the original investment, so it's a loss-making exit. This removes a drag but also signals past acquisition troubles.
This divestiture is a negative event that highlights management challenges and past poor performance, affecting investor confidence.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 202631 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

August 202631 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

Latest31 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.